In short
Forecast raised- The development pipelines are generally progressing as planned, and KP2011 is being prepared for the domestic Phase 3 trial.
- For the nine months through the third quarter, there was no revenue, while selling, general and administrative expenses were ¥765 million, operating loss was ¥765 million and net loss for the quarter was ¥847 million.
- The full-year forecasts for selling, general and administrative expenses and losses were revised based on progress in research and development and cost controls.
What they reported
this period against the same period a year earlier, and where they now expect the year to endOperating profit
| Period | ¥bn |
|---|---|
| FY24/12 Q1 | -0.2 |
| FY24/12 Q2 | -0.2 |
| FY24/12 Q3 | -0.2 |
| FY24/12 Q4 | -0.2 |
| FY25/12 Q1 | -0.2 |
| FY25/12 Q2 | -0.2 |
| FY25/12 Q3 | -0.2 |
| FY25/12 Q4 | -0.2 |
| FY26/12 Q1 | -0.2 |
| FY26/12 Q2 | -0.2 |
| FY26/12 Q3 | -0.3 |
Research and development expenses increased from the same period of the previous year but remained below the initial assumptions.
各開発パイプラインは全般的に計画通り進捗。研究開発費は前年同期比で増加したものの、期初の想定を下回って推移。The full-year earnings forecast was revised based on actual results through the third quarter.
第3四半期までの実績を踏まえ、通期業績予想を修正(「2026年12月期 通期見通し」参照)。Net profit
| Period | ¥bn |
|---|---|
| FY24/12 Q1 | -0.2 |
| FY24/12 Q2 | -0.2 |
| FY24/12 Q3 | -0.2 |
| FY24/12 Q4 | -0.2 |
| FY25/12 Q1 | -0.2 |
| FY25/12 Q2 | -0.2 |
| FY25/12 Q3 | -0.2 |
| FY25/12 Q4 | -0.3 |
| FY26/12 Q1 | -0.3 |
| FY26/12 Q2 | -0.2 |
| FY26/12 Q3 | -0.4 |
Net loss for the quarter includes an impairment loss of ¥61 million.
減損損失61百万円を計上The full-year forecast for net loss was revised from ¥1,616 million to ¥1,192 million.
Their own numbers
figures this company chose to report, a year ago against nowThe number of employees was 21 as of 30 September 2026.
The KP2011 clinical trial indicated the potential to delay disease progression by 27.9 weeks.
Two patients showed improved motor function in the clinical study.
The low–high ranges are Komori's estimate, not figures the company gave.
Everything else in the deck
New initiatives
- A sustained-release granule formulation was newly developed for KP2011 to improve patient convenience and quality of life.
- For KP8011, the company is proceeding with the transfer of technology to Nikon Cell Innovation and establishing a manufacturing system for cells for company-sponsored clinical trials.
- The company was selected for AMED’s Program to Accelerate the Realization of Regenerative, Cellular and Gene Therapies and joined the program as a collaborating company.
- The company is considering launching multiple new central nervous system development pipelines using disease-specific iPS cells.
What decks usually leave out
COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deckMargins and overheads
Overheads (selling and admin costs): ¥765.0m
Financial targets
| Period | % |
|---|---|
| FY24/12 | -31.6 |
| FY25/12 | -56.4 |
| FY26/12 | -141.6 |
| Period | % |
|---|---|
| FY23/12 | 93.7 |
| FY24/12 | 96.0 |
| FY25/12 | 43.1 |
| FY26/12 | 18.8 |
Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.
How they rate themselves against plan
The company explained that the development pipelines are generally progressing as planned.
各開発パイプラインは全般的に計画通り進捗。Headcount
Market size and share
The company's slice (blue) is drawn magnified so a small share stays visible; compare it with its own dashed outline from a year ago.